EBR Systems, Inc. (ASX: EBR) has secured a significant reimbursement milestone for its WiSE Cardiac Resynchronization Therapy System after the United States Centers for Medicare & Medicaid Services finalised higher inpatient payment classifications that can increase base Medicare reimbursement by approximately 58% to 93% for eligible procedures from October 1, 2026.
Under the FY2027 Inpatient Prospective Payment System, eligible WiSE procedures are being shifted into diagnosis-related groups aligned more closely with leadless pacemaker procedures. EBR Systems, Inc. said the relevant base payment could increase from approximately US$23,233 to US$36,694 in one category and from approximately US$13,153 to US$25,421 in another.
When combined with the maximum New Technology Add-on Payment of up to US$41,145, total Medicare reimbursement may reach approximately US$77,839 for an eligible procedure under MS-DRG 228 and US$66,566 under MS-DRG 229. Actual reimbursement varies by hospital, patient circumstances and eligibility, so the maximum figures should not be read as a guaranteed payment for every WiSE implant.
Why is Medicare reimbursement so important to EBR Systems’ WiSE rollout?
FDA approval determines whether a medical device can be marketed, but hospital economics can determine how quickly it is actually adopted. Providers need confidence that payments will appropriately reflect the cost, staff time and resources required to perform a procedure.
That is particularly relevant for EBR Systems, Inc. because WiSE represents a novel approach to cardiac resynchronization therapy. The system provides leadless left-ventricular endocardial pacing for heart-failure patients for whom conventional CRT may have failed, been ineffective or presented excessive procedural risk.
CMS concluded that the WiSE electrode is more closely aligned clinically with leadless pacemaker procedures than conventional pacemaker procedures. The final FY2027 rule therefore assigns the relevant procedure code to MS-DRGs 228 and 229, which carry higher reimbursement than the categories in which eligible procedures had previously been grouped.
For EBR Systems, Inc., that classification could reduce an important source of friction during hospital contracting. A physician may want to use a technology, but hospital administrators also need clarity over reimbursement before establishing a repeatable commercial programme.
How far has EBR Systems, Inc. progressed with commercial WiSE implants?
The reimbursement improvement arrives while EBR Systems, Inc. is still in the relatively early stages of its United States commercial launch.
During the second quarter of 2026, the company completed 46 commercial WiSE implants, bringing cumulative procedures across the pilot phase and Limited Market Release to 117. It also signed 17 new purchasing contracts during the quarter, lifting the cumulative total to 52, and trained another 26 physicians, taking the total number of trained physicians to 90.
More than half of activated hospital accounts had completed at least three WiSE implants by the end of the quarter. That metric is particularly important because sustainable commercialisation depends on repeat utilisation rather than simply signing hospitals that perform one procedure and then stop.
EBR Systems, Inc. expected second-quarter revenue of approximately US$2.50 million-US$2.60 million based on preliminary unaudited figures. The company has increasingly shifted its commercial organisation from signing additional sites toward driving deeper utilisation within hospitals already activated.
Higher Medicare reimbursement can support that strategy because hospitals already familiar with WiSE now have greater payment clarity when considering additional eligible patients.
Does the new reimbursement decision mean nationwide Medicare coverage is complete?
No. The payment-classification decision and national Medicare coverage process are related to commercial access but are distinct regulatory and reimbursement mechanisms.
CMS formally opened a National Coverage Analysis for WiSE CRT on June 3, 2026. The review is examining clinical evidence and patient characteristics relevant to determining when Medicare should cover the therapy nationally, with completion currently expected by March 3, 2027.
That distinction is important for investors. The September 21 announcement improves how eligible inpatient procedures can be paid, but a broader national coverage determination could influence consistency of access across Medicare beneficiaries and hospitals.
The CMS review specifically recognises that WiSE seeks to extend CRT to patients for whom traditional therapy has been unsuccessful, ineffective or considered too risky. The agency has requested clinical evidence addressing outcomes including mortality, heart-failure hospitalisations and patient characteristics that may predict benefit.
The reimbursement milestone therefore strengthens one part of the commercial framework while the national coverage process continues.
Why is EBR Systems stock still carrying significant market scepticism?
EBR Systems, Inc. entered September 21 after closing the previous session around A$0.26. Despite periodic rallies, the stock remained down sharply during 2026, reflecting the market’s concerns around commercial execution, funding requirements and the time needed to convert regulatory approval into a scalable medical-device business.
That share-price history is useful context for the CMS decision. Investors are not merely asking whether WiSE is clinically differentiated. They are asking how quickly hospitals adopt it, how much revenue each activated account generates, how much cash commercial expansion consumes and when higher procedure volumes can support a sustainable business model.
EBR Systems, Inc. ended June with substantial liquidity following its financing programme, giving it resources to build sales, training, field support and manufacturing capacity. But a medical-device commercial launch can consume significant capital before revenue reaches scale.
Reimbursement can address one of those adoption barriers, but it cannot guarantee physician referrals, successful hospital contracting, procedural capacity or repeat utilisation.
What changes for the EBR Systems investment case after September 21?
The clearest change is that eligible hospitals now have a stronger economic framework for performing WiSE procedures under Medicare. A base-payment increase of 58% to 93% is large enough to matter when hospital finance teams evaluate whether reimbursement adequately compensates for the resources required.
The second potential benefit is commercial predictability. EBR Systems, Inc. can approach hospitals with a clearer FY2027 payment structure rather than asking customers to adopt a new device amid substantial uncertainty over inpatient reimbursement.
The remaining challenge is turning that improved framework into utilisation. The most revealing future numbers will be implants per activated account, quarterly revenue growth, hospital reorder behaviour and the progression of the CMS national coverage review.
EBR Systems, Inc. has therefore cleared another important commercial hurdle without clearing all of them. WiSE now has a considerably stronger inpatient reimbursement pathway from October 1, but the ultimate value of that victory will be measured in patients treated repeatedly across an expanding network of hospitals rather than in reimbursement rates alone.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
